ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Comparator 1

Its studies are mostly in Influenza, Human, led by GlaxoSmithKline.

Furthest: phase 2, since Aug 6, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline20 open or runningphase 2since Aug 6, 2025Aug 6, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2025First study: phase 2 study in Influenza, HumanFirst studyNCT07121192 · 776 enrolled · United States
  2. Oct 1, 2025Phase 2 study in Influenza, HumanNCT07204964 · 971 enrolled · United States, Belgium

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07204964Influenza, Human · United States, Belgium2CompletedAug 24, 2026971
NCT07121192Influenza, Human · United States2CompletedMay 11, 2026776

How it is read

Names in the registry

  • “Comparator 1”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.